# Surrozen, Inc.: overview SRZN · Nasdaq · CIK 1824893 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/srzn.md) · [Financials](/companies/srzn/financials.md) · [Filings](/companies/srzn/filings.md) · [Insiders](/companies/srzn/insiders.md) Latest reported revenue: [$5.0m](/filings/0001193125-26-338120.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-338120). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [10.0](/filings/0001193125-25-272422.md) | [0.7 d](/filings/0001193125-26-119818.md) | [1.0](/filings/0001193125-26-209179.md) | [1.0](/filings/0001193125-26-338120.md) | [1.0](/filings/0001193125-25-272422.md) | [0.5 d](/filings/0001193125-26-119818.md) | [5.0](/filings/0001193125-26-209179.md) | [5.0](/filings/0001193125-26-338120.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [12.3%](/filings/0001193125-25-272422.md) | [(1311.8%) d](/filings/0001193125-26-119818.md) | [(971.6%)](/filings/0001193125-26-209179.md) | [(917.3%)](/filings/0001193125-26-338120.md) | [(1107.3%)](/filings/0001193125-25-272422.md) | [(2393.8%) d](/filings/0001193125-26-119818.md) | [(209.1%)](/filings/0001193125-26-209179.md) | [(207.4%)](/filings/0001193125-26-338120.md) | | Net margin | % | [(14.3%)](/filings/0001193125-25-272422.md) | [(4280.8%) d](/filings/0001193125-26-119818.md) | [(2743.6%)](/filings/0001193125-26-209179.md) | [4043.3%](/filings/0001193125-26-338120.md) | [(7288.2%)](/filings/0001193125-25-272422.md) | [(34689.2%) d](/filings/0001193125-26-119818.md) | [(2550.1%)](/filings/0001193125-26-209179.md) | [1003.5%](/filings/0001193125-26-338120.md) | | Diluted EPS | $ per share | [(0.44)](/filings/0001193125-25-272422.md) | not reported | [(7.43)](/filings/0001193125-26-209179.md) | [2.55](/filings/0001193125-26-338120.md) | [(8.36)](/filings/0001193125-25-272422.md) | not reported | [(11.65)](/filings/0001193125-26-209179.md) | [(0.41)](/filings/0001193125-26-338120.md) | | Free cash flow | $m | [(6.8) d](/filings/0001193125-25-272422.md) | [3.5 d](/filings/0001193125-26-119818.md) | [(9.3)](/filings/0001193125-26-209179.md) | [(6.1) d](/filings/0001193125-26-338120.md) | [(9.1) d](/filings/0001193125-25-272422.md) | [(5.9) d](/filings/0001193125-26-119818.md) | [(12.6)](/filings/0001193125-26-209179.md) | [(7.4) d](/filings/0001193125-26-338120.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0000950170-23-011118.md) | [12.5](/filings/0000950170-24-043399.md) | [0.0](/filings/0000950170-25-047712.md) | [10.7](/filings/0001193125-26-119818.md) | [3.5](/filings/0001193125-26-119818.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(354.7%)](/filings/0000950170-24-043399.md) | not reported | [(239.7%)](/filings/0001193125-26-119818.md) | [(1210.6%)](/filings/0001193125-26-119818.md) | | Net margin | % | not reported | [(288.0%)](/filings/0000950170-24-043399.md) | not reported | [(596.6%)](/filings/0001193125-26-119818.md) | [(6960.8%)](/filings/0001193125-26-119818.md) | | Diluted EPS | $ per share | [(2.21)](/filings/0000950170-23-011118.md) | [(15.56)](/filings/0000950170-24-043399.md) | [(21.33)](/filings/0000950170-25-047712.md) | [(21.67)](/filings/0001193125-26-119818.md) | [(32.37)](/filings/0001193125-26-119818.md) | | Free cash flow | $m | [(50.1)](/filings/0000950170-23-011118.md) | [(44.9)](/filings/0000950170-24-043399.md) | [(40.8)](/filings/0000950170-25-047712.md) | [(17.7)](/filings/0001193125-26-119818.md) | [(30.4)](/filings/0001193125-26-119818.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/srzn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $38.2m | 1,473,101 | | Unchanged | | [Boxer Capital Management, LLC](/funds/2018299.md) | 2026-06-30 | $27.0m | 1,105,683 | | Added +339,365 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $17.7m | 683,079 | | Reduced −48,059 | | [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $17.2m | 664,272 | | New +664,272 | | [Venrock Adviser, LLC](/funds/1615982.md) | 2026-06-30 | $16.4m | 632,931 | | Unchanged | | [STEMPOINT CAPITAL LP](/funds/1952142.md) | 2026-06-30 | $13.8m | 602,798 | | Added +77,159 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $13.1m | 503,985 | | Added +274,592 | | [Spruce Street Capital LP](/funds/2050194.md) | 2026-06-30 | $11.2m | 432,040 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $10.2m | 394,864 | | Added +367,013 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $10.2m | 392,550 | | Added +223,458 | ## Recent filings [All 494 filings](/companies/srzn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 20:45 ET | [SCHEDULE 13D/A](/filings/0001193125-26-429027.md) | Ownership report, active investor, amended | 0001193125-26-429027 | | 2026-10-20 | 21:04 ET | [8-K](/filings/0001193125-26-426828.md) | 2.02 Results of operations; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-426828 | | 2026-10-02 | 12:05 ET | [8-K](/filings/0001193125-26-411298.md) | 8.01 Other events | 0001193125-26-411298 | | 2026-08-06 | 20:23 ET | [10-Q](/filings/0001193125-26-338120.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338120 | | 2026-08-06 | 20:15 ET | [8-K](/filings/0001193125-26-338068.md) | 2.02 Results of operations | 0001193125-26-338068 | | 2026-05-18 | 10:49 ET | [SCHEDULE 13D/A](/filings/0001193125-26-227857.md) | Ownership report, active investor, amended | 0001193125-26-227857 | | 2026-05-14 | 20:13 ET | [8-K](/filings/0001193125-26-224037.md) | 5.07 Shareholder vote results | 0001193125-26-224037 | | 2026-05-06 | 20:38 ET | [10-Q](/filings/0001193125-26-209179.md) | Quarterly report, period 2026-03-31 | 0001193125-26-209179 | | 2026-05-06 | 20:15 ET | [8-K](/filings/0001193125-26-208999.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-208999 | | 2026-04-01 | 20:23 ET | [DEF 14A](/filings/0001193125-26-137976.md) | Proxy statement, period 2026-04-01 | 0001193125-26-137976 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-119818.md), filed Mar 23, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1824893 - Tickers: SRZN - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.